Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609999 · ClinicalTrials.gov registry record · Phase 1
Ph I Dasatinib + Erlotinib in Recurrent MG
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00609999 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 47 participants.
The verdict
NCT00609999, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
Primary: To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG Secondary: To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on \& not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with this regimen in this patient population
Interventions
- DRUG Erlotinib and Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609999
The ClinicalTrials.gov registry entry for NCT00609999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib and Dasatinib is the first listed.
NCT00609999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609999 about?
NCT00609999 is a clinical study titled "Ph I Dasatinib + Erlotinib in Recurrent MG". Primary: To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG Secondary: To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recur...
What is the current status of trial NCT00609999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2008-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00609999?
The interventions under investigation include: Erlotinib and Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00609999?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.